Michitaka Matsuda

Senior Researcher

National Center For Global Health and Medicine
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Year:

2025

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis, and cirrhosis are major risk factors for hepatocellular carcinoma (HCC), yet current blood-based diagnostic assays lack sufficient accuracy for routine clinical use. Identifying a non-invasive molecular signature that accurately detects liver disease could improve early diagnosis and monitoring. We hypothesized that the Liver FibraChek Dx© serum assay could discriminate MASLD and HCC from healthy controls using a multiplex biomarker-based algorithm. AIM To evaluate the diagnostic performance of the Liver FibraChek Dx© assay for detecting MASLD and HCC. METHODS This was a prospective, single-center study conducted in a United States tertiary care setting. Serum samples were collected from 45 participants (14 MASLD, 19 HCC, 12 healthy controls) with liver histology confirmed by biopsy. The Liver FibraChek Dx© algorithm integrates weighted values of aspartate aminotransferase, alanine aminotransferase, taurocholic acid, L-tyrosine, platelet count, and patient age to generate a risk score. Wilcoxon rank sum tests were used to assess associations with histologic diagnosis, and receiver operating characteristic (ROC) curves quantified diagnostic performance. RESULTS Liver FibraChek Dx© risk scores were significantly elevated in MASLD and HCC compared to controls (median: 6.92 ± 3.86 vs 3.61 ± 1.67, P < 0.001). The area under the ROC curve was 0.890 (95%CI: 0.776–1.000) for distinguishing diseased from healthy individuals. Sensitivity was 93.9%, specificity 75.0%, positive predictive value 91.1%, negative predictive value 81.8%, and overall accuracy 88.9%. CONCLUSION The Liver FibraChek Dx© assay accurately detects liver disease and shows promise as a non-invasive tool for diagnosing and monitoring MASLD and HCC.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis, and cirrhosis are risk factors for hepatocellular carcinoma (HCC). Blood-based assays to date have limited accuracy for detecting MASLD and cirrhosis, and thus have not been widely adopted in the clinical setting. The identification and validation of a multiplex molecular signature associated with liver disease may address this unmet need. This prospective single-center US study evaluated the performance of the non-invasive Liver FibraChek Dx serum assay for detecting MASLD. The study algorithm analyzes weighted values of five serum biomarkers (AST, ALT, taurocholic acid, L-tyrosine, and platelet count) plus age to derive a risk score. Samples comprised 14 MASLD cases, 19 HCC cases, and 12 healthy controls. Liver status was confirmed by tissue biopsy. Wilcoxon rank sum tests determined the association between the risk score and confirmed liver histology. Diagnostic performance was assessed using ROC curves. The probability of identifying MASLD and/or HCC by Liver FibraChek Dx, in conjunction with other patient parameters, was demonstrated by an AUROC of 0.890 (95% CI: 0.776-1.000), with 93.9% sensitivity, 75.0% specificity, 91.1% positive predictive value, 81.8% negative predictive value, and 88.9% accuracy. Risk scores associated with the biomarker panel enabled accurate discrimination of liver disease from healthy controls. The non-invasive multiplex Liver FibraChek Dx test can effectively and accurately detect and classify hepatic fibrosis risk in peripheral blood samples and may have utility in diagnosing and monitoring liver pathogenesis. Citation Format: Fernando Siguencia, Michitaka Matsuda, Vijay Pandyarajan, Sunao Tanaka, Steven M Smith, Ekihiro Seki, Charles J Rosser, Hideki Furuya. Evaluate the performance of FibraChek™ for non-invasive detection of hepatic fibrosis and hepatocellular carcinoma [abstract]. In: Proceedings of the AACR Special Conference: Liquid Biopsy: From Discovery to Clinical Implementation; 2024 Nov 13-16; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(21_Suppl):Abstract nr A068.

Year:

2024

Background: The prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) has increased in recent decades. Approximately 25% of patients with MASLD progress to metabolic dysfunction–associated steatohepatitis, which is characterized by hepatic steatosis plus hepatocyte damage, inflammation, and fibrosis. We previously reported that Neurotropin (NTP), a drug used for relieving pain in Japan and China, inhibits lipid accumulation in hepatocytes by preventing mitochondrial dysfunction. We hypothesized that inhibiting hepatic steatosis and inflammation by NTP can be an effective strategy for treating MASLD and tested this hypothesis in a MASLD mouse model. Methods: Six-week-old C57BL/6NJ male mice were fed a normal diet and normal drinking water or a high-fat diet with high fructose/glucose water for 12 weeks. During the last 6 weeks, the mice were also given high-dose NTP, low-dose NTP, or control treatment. Histologic, biochemical, and functional tests were conducted. MitoPlex, a new proteomic platform, was used to measure mitochondrial proteins, as mitochondrial dysfunction was previously reported to be associated with MASLD progression. Results: NTP inhibited the development of hepatic steatosis, injury, inflammation, and fibrosis induced by feeding a high-fat diet plus high fructose/glucose in drinking water. NTP also inhibited HSC activation. MitoPlex analysis revealed that NTP upregulated the expression of mitochondrial proteins related to oxidative phosphorylation, the tricarboxylic acid cycle, mitochondrial dynamics, and fatty acid transport. Conclusions: Our results indicate that NTP prevents the development of hepatic steatosis, injury, and inflammation by preserving mitochondrial function in the liver and inhibits liver fibrosis by suppressing HSC activation. Thus, repurposing NTP may be a beneficial option for treating MASLD/metabolic dysfunction–associated steatohepatitis.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Jun Inoue

Associate Professor

Tohoku University Hospital

JAPAN
View details

Alexander Xu

Assistant Professor

University of Maryland at College Park

UNITED STATES
View details

Ramachandran Murali

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Maria Lauda Tomasi

Cedars-Sinai Medical Center

UNITED STATES
View details

Yoon Mee Yang

Associate Professor

Sungkyunkwan University

SOUTH KOREA
View details